Clinical Trial Update: Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety of donor dendritic cells and donor lymphocyte infusions in patients with relapsed hematologic malignancies after allogeneic trans…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• Donor Dendritic Cells
• Donor Lymphocytes

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Hematologic Malignancy | Phase 1 | Status: COMPLETED